Amyloid Seeds Emerge as Blood Biomarker - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Amyloid Seeds Emerge as Blood Biomarker

Plasma aggregation activity separates Alzheimer’s disease from non-Alzheimer’s dementias

  • September 8, 2026

  • 3 min

Share

Clinical Scorecard: Amyloid Seeds Emerge as Blood Biomarker

At a Glance

CategoryDetail
ConditionAlzheimer's disease and mild cognitive impairment due to Alzheimer's disease
Key MechanismsDetection of amyloid beta aggregation seeding activity in plasma using protein misfolding cyclic amplification
Target PopulationPatients with Alzheimer's disease, mild cognitive impairment due to Alzheimer's disease, and other dementias
Care SettingClinical assessment in a hospital setting

Key Highlights

  • Blood test distinguishes Alzheimer's disease and MCI from normal cognition and other dementias
  • Assay has an area under the curve of 0.93 for Alzheimer's disease vs. normal cognition
  • Results available within 24 hours
  • Higher plasma seeding activity correlates with poorer cognitive performance
  • Validation needed in diverse populations

Guideline-Based Recommendations

Diagnosis

  • Use clinical criteria for diagnosing Alzheimer's disease and MCI

Management

  • Consider blood test for distinguishing Alzheimer's disease from other dementias

Monitoring & Follow-up

  • Monitor cognitive performance and dementia severity in relation to plasma seeding activity

Risks

  • Limitations include reliance on clinical criteria and lack of neuropathologic confirmation

Patient & Prescribing Data

549 patients including cognitively unimpaired, MCI, and dementia patients

Test performance similar in discovery and validation groups

Clinical Best Practices

  • Assess amyloid beta seeding activity in patients with suspected Alzheimer's disease
  • Utilize the assay in conjunction with clinical evaluations

Related Resources & Content

Original Source(s)

Amyloid Seeds Emerge as Blood Biomarker

  • September 8, 2026

Related Content

Triple-positive profile may flag adverse prostate cancer pathology

A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.

Crowdsourcing Med Ed: The Pathology Portal

When the pathology community pools its learning resources, great things can be achieved in continuous education, explains Jo Martin

Estriol may ease menopause-related cognitive decline

Women reported improvement across 6 cognitive domains during 12 months of estriol-based treatment, while murine models suggested a potential astrocyte-mediated mechanism.